Clinical trial
A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of HZN-1116 in Participants With Sjögren's Syndrome
NCT06312020 is registered in ClinicalTrials.gov with Amgen as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of HZN-1116 in Participants With Sjögren's Syndrome
- Lead sponsor
- Amgen
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- May 9, 2024
- Completion date
- April 28, 2026
- Enrollment
- 209 (actual)
- Sites
- 66
Conditions
As the registry lists them; a condition with its own page is linked.